BRPI1009919A2 - combinações de pentamidina para tratamento de câncer. - Google Patents
combinações de pentamidina para tratamento de câncer.Info
- Publication number
- BRPI1009919A2 BRPI1009919A2 BRPI1009919A BRPI1009919A BRPI1009919A2 BR PI1009919 A2 BRPI1009919 A2 BR PI1009919A2 BR PI1009919 A BRPI1009919 A BR PI1009919A BR PI1009919 A BRPI1009919 A BR PI1009919A BR PI1009919 A2 BRPI1009919 A2 BR PI1009919A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer treatment
- pentamidine
- combinations
- pentamidine combinations
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17480209P | 2009-05-01 | 2009-05-01 | |
| US29659010P | 2010-01-20 | 2010-01-20 | |
| PCT/IB2010/001012 WO2010125462A2 (en) | 2009-05-01 | 2010-05-03 | Pentamidine combinations for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1009919A2 true BRPI1009919A2 (pt) | 2017-03-28 |
Family
ID=43032617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1009919A BRPI1009919A2 (pt) | 2009-05-01 | 2010-05-03 | combinações de pentamidina para tratamento de câncer. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120128667A1 (pt) |
| EP (1) | EP2424516A4 (pt) |
| JP (1) | JP2012525371A (pt) |
| CN (1) | CN102573826A (pt) |
| AU (1) | AU2010243267A1 (pt) |
| BR (1) | BRPI1009919A2 (pt) |
| CA (1) | CA2758856A1 (pt) |
| NZ (1) | NZ596365A (pt) |
| RU (1) | RU2011142806A (pt) |
| WO (1) | WO2010125462A2 (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9662308B2 (en) | 2008-02-01 | 2017-05-30 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg | Orally bioavailable pentamidine prodrugs for the treatment of diseases |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| WO2014008592A1 (en) * | 2012-07-13 | 2014-01-16 | Oncozyme Pharma Inc. | Combinations comprising diamidine compounds and parp inhibitors for use iν treating cancer |
| WO2014077915A1 (en) | 2012-11-14 | 2014-05-22 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying malignant skin lesions |
| BR112015014836A2 (pt) * | 2012-12-21 | 2017-07-11 | Verlyx Pharma Inc | método para tratamento alvo de uma ou mais condições do fígado, e, uso oral de uma quantidade terapeuticamente eficaz de pelo menos um análogo de diamidina ou um sal farmaceuticamente aceitável da mesma |
| ES2532150B1 (es) * | 2013-09-23 | 2015-11-30 | Universidad Autónoma de Madrid | Compuestos para el tratamiento del cáncer |
| US20170275700A1 (en) | 2014-08-14 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| JP7042739B2 (ja) | 2015-08-20 | 2022-03-28 | イプセン バイオファーム リミティド | 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法 |
| TW202400181A (zh) * | 2015-08-21 | 2024-01-01 | 英商益普生生物製藥有限公司 | 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法 |
| WO2017192863A1 (en) * | 2016-05-04 | 2017-11-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
| AU2017261688B2 (en) | 2016-05-10 | 2022-09-29 | Mayo Foundation For Medical Education And Research | Methods and materials for staging and treating skin cancer |
| CN110402163A (zh) | 2016-11-02 | 2019-11-01 | 易普森生物制药有限公司 | 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌 |
| CN113039289B (zh) | 2018-07-25 | 2025-11-07 | 斯凯莱恩迪艾克斯有限公司 | 预测黑色素瘤转移和患者预后的基因特征 |
| US12398105B2 (en) | 2018-12-20 | 2025-08-26 | Auransa Inc. | Analogues of pentamidine and uses therefor |
| JP7216829B2 (ja) * | 2019-02-22 | 2023-02-01 | ノボキュア ゲーエムベーハー | Ｘｅｌｏｘ又はｆｏｌｆｏｘと組み合わせたｔｔフィールドを用いる胃癌の治療 |
| CN111803475B (zh) * | 2019-04-10 | 2023-06-23 | 中美（河南）荷美尔肿瘤研究院 | 喷他脒在制备抑制pd1和pd-l1蛋白之间相互作用药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1231910T3 (da) * | 1999-11-16 | 2009-08-31 | Oncozyme Pharma Inc | Pentamidin til behandling af cancer |
| US6569853B1 (en) * | 2000-11-06 | 2003-05-27 | Combinatorx, Incorporated | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
| AU2003241346A1 (en) * | 2002-05-01 | 2003-11-17 | The Cleveland Clinic Foundation | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer |
| US20040116407A1 (en) * | 2002-07-11 | 2004-06-17 | Alexis Borisy | Combinations of drugs for the treatment of neoplasms |
| PE20050206A1 (es) * | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
| US20050054708A1 (en) * | 2003-07-28 | 2005-03-10 | Nichols Matthew James | Combinations of drugs for the treatment of neoplasms |
-
2010
- 2010-05-03 RU RU2011142806/15A patent/RU2011142806A/ru not_active Application Discontinuation
- 2010-05-03 BR BRPI1009919A patent/BRPI1009919A2/pt not_active IP Right Cessation
- 2010-05-03 AU AU2010243267A patent/AU2010243267A1/en not_active Abandoned
- 2010-05-03 CN CN2010800193678A patent/CN102573826A/zh active Pending
- 2010-05-03 CA CA2758856A patent/CA2758856A1/en not_active Abandoned
- 2010-05-03 US US13/318,197 patent/US20120128667A1/en not_active Abandoned
- 2010-05-03 WO PCT/IB2010/001012 patent/WO2010125462A2/en not_active Ceased
- 2010-05-03 JP JP2012507844A patent/JP2012525371A/ja active Pending
- 2010-05-03 EP EP10769389.7A patent/EP2424516A4/en not_active Withdrawn
- 2010-05-03 NZ NZ596365A patent/NZ596365A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010125462A3 (en) | 2011-01-06 |
| AU2010243267A1 (en) | 2011-11-10 |
| WO2010125462A2 (en) | 2010-11-04 |
| RU2011142806A (ru) | 2013-06-10 |
| WO2010125462A4 (en) | 2011-02-24 |
| CA2758856A1 (en) | 2010-11-04 |
| CN102573826A (zh) | 2012-07-11 |
| NZ596365A (en) | 2013-11-29 |
| US20120128667A1 (en) | 2012-05-24 |
| EP2424516A4 (en) | 2014-04-02 |
| JP2012525371A (ja) | 2012-10-22 |
| EP2424516A2 (en) | 2012-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1009919A2 (pt) | combinações de pentamidina para tratamento de câncer. | |
| BR112012005594A2 (pt) | tratamento de câncer | |
| BRPI1007995A2 (pt) | orto-aminoamidas para o tratamento de cãncer. | |
| BRPI1010849A2 (pt) | parafuso para ossos. | |
| BRPI1013618A2 (pt) | pirimidinas substituídas para o tratamento de câncer | |
| EP2382331A4 (en) | KREBSBIOMARKER | |
| BR112012001490A2 (pt) | aparelho para alimentação. | |
| PT2456889E (pt) | Marcadores para o cancro do endométrio | |
| BRPI1010874A8 (pt) | composição para o tratamento de câncer de próstata | |
| BRPI0922884A2 (pt) | compostos para tratamento de câncer | |
| EP2627333A4 (en) | Combination treatment of cancer | |
| BR112012000502A2 (pt) | terapia de combinação para o tratamento de diabetes | |
| BRPI1007972A2 (pt) | composições de combinação e métodos para o tratamento de câncer | |
| BR112012002797A2 (pt) | tratamento de câncer de próstata | |
| BRPI0920952A2 (pt) | vaso de tratamento intregrado para correntes de resíduos | |
| BRPI1014802A2 (pt) | pró-fármacos de triptolida. | |
| BRPI0909016A2 (pt) | anticorpos úteis para o tratamento do câncer | |
| IT1396487B1 (it) | Convogliatore. | |
| BRPI0818170A2 (pt) | 5-cianotienopiridinas para o tratamento de tumores. | |
| BRPI0922367A2 (pt) | enzastaurin para o tratamento de câncer | |
| BRPI1008706A2 (pt) | dispositivo para diagnóstico. | |
| SMT201600296B (it) | Lapatinib per il trattamento del cancro | |
| BRPI1009435A2 (pt) | tratamento para câncer no pâncreas | |
| BRPI1008016A2 (pt) | método para o tratamento de águas residuais | |
| BRPI0918508A2 (pt) | orto-aminoanilidas para o tratamento de câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |